$PIII
P3 Health Partners Inc.

2021 Q4 Form 8-K Financial Statement

#000110465923116284 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2021 Q4 2020 Q3
Revenue $58.76M $128.8M
YoY Change -52.94%
Cost Of Revenue $200.1M $127.0M
YoY Change 45.79%
Gross Profit -$22.25M $1.825M
YoY Change 79.74%
Gross Profit Margin -37.86% 1.42%
Selling, General & Admin $17.35M $14.02M
YoY Change -0.81%
% of Gross Profit 768.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $187.6K $613.3K
YoY Change 3.14%
% of Gross Profit 33.61%
Operating Expenses $117.7M $15.34M
YoY Change -7621.42%
Operating Profit -$58.89M -$13.51M
YoY Change 444.57%
Interest Expense $2.131M -$2.317M
YoY Change -168.91%
% of Operating Profit
Other Income/Expense, Net $949.7K $0.00
YoY Change -426.73%
Pretax Income -$57.94M -$15.83M
YoY Change 308.1%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.08M -$16.71M
YoY Change -24.43%
Net Earnings / Revenue -17.16% -12.97%
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.24 -$68.58K
COMMON SHARES
Basic Shares Outstanding 41.58M
Diluted Shares Outstanding 41.58M

Balance Sheet

Concept 2021 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.5M
YoY Change
Cash & Equivalents $140.5M
Short-Term Investments
Other Short-Term Assets $7.315M
YoY Change
Inventory
Prepaid Expenses $355.2K
Receivables $51.34M
Other Receivables $726.9K
Total Short-Term Assets $199.9M
YoY Change 50502.83%
LONG-TERM ASSETS
Property, Plant & Equipment $8.048M
YoY Change 30.85%
Goodwill $1.310B
YoY Change 150251.06%
Intangibles $835.8M
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.61M
YoY Change
Total Long-Term Assets $2.164B
YoY Change
TOTAL ASSETS
Total Short-Term Assets $199.9M
Total Long-Term Assets $2.164B
Total Assets $2.364B
YoY Change 598469.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $124.5M
YoY Change
Accrued Expenses $52.91M
YoY Change 2314469.99%
Deferred Revenue
YoY Change
Short-Term Debt $3.579M
YoY Change
Long-Term Debt Due $46.10K
YoY Change -48.77%
Total Short-Term Liabilities $198.8M
YoY Change 53298.41%
LONG-TERM LIABILITIES
Long-Term Debt $80.00M
YoY Change 76.26%
Other Long-Term Liabilities $21.17M
YoY Change
Total Long-Term Liabilities $101.2M
YoY Change 82.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $198.8M
Total Long-Term Liabilities $101.2M
Total Liabilities $299.9M
YoY Change 80475.68%
SHAREHOLDERS EQUITY
Retained Earnings -$39.42M
YoY Change 1724227.38%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $273.6M $0.00
YoY Change
Total Liabilities & Shareholders Equity $2.364B
YoY Change 598469.09%

Cashflow Statement

Concept 2021 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$10.08M -$16.71M
YoY Change -24.43%
Depreciation, Depletion And Amortization $187.6K $613.3K
YoY Change 3.14%
Cash From Operating Activities -$15.34M -$6.645M
YoY Change -14.53%
INVESTING ACTIVITIES
Capital Expenditures $120.6K -$2.233M
YoY Change -117.37%
Acquisitions
YoY Change
Other Investing Activities -$47.76M $336.1K
YoY Change 8196.58%
Cash From Investing Activities -$47.86M -$1.897M
YoY Change 3669.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$180.0K
YoY Change
Debt Paid & Issued, Net $8.008K
YoY Change
Cash From Financing Activities 198.7M -21.87K
YoY Change 471.21%
NET CHANGE
Cash From Operating Activities -15.34M -6.645M
Cash From Investing Activities -47.86M -1.897M
Cash From Financing Activities 198.7M -21.87K
Net Change In Cash 135.5M -8.564M
YoY Change 770.6%
FREE CASH FLOW
Cash From Operating Activities -$15.34M -$6.645M
Capital Expenditures $120.6K -$2.233M
Free Cash Flow -$15.46M -$4.412M
YoY Change -10.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001832511
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Document Type
DocumentType
8-K
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-11-09
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
P3 Health Partners Inc.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity File Number
EntityFileNumber
001-40033
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2992794
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
2370 Corporate Circle, Suite 300
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89074
CY2023Q4 dei City Area Code
CityAreaCode
702
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
910-3950
CY2023Q4 dei Written Communications
WrittenCommunications
false
CY2023Q4 dei Soliciting Material
SolicitingMaterial
false
CY2023Q4 dei Pre Commencement Tender Offer
PreCommencementTenderOffer
false
CY2023Q4 dei Pre Commencement Issuer Tender Offer
PreCommencementIssuerTenderOffer
false
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100935
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179512
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
355188
CY2021Q4 us-gaap Assets Current
AssetsCurrent
456123
CY2020Q4 us-gaap Assets Current
AssetsCurrent
179512
CY2020Q4 piii Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
215448
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
316267136
CY2021Q4 us-gaap Assets
Assets
316723259
CY2020Q4 us-gaap Assets
Assets
394960
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21284300
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2286
CY2021Q4 piii Accrued Offering Costs Current
AccruedOfferingCostsCurrent
15450
CY2020Q4 piii Accrued Offering Costs Current
AccruedOfferingCostsCurrent
94960
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
150000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
275000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21449750
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
372246
CY2021Q4 piii Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
13213259
CY2021Q4 us-gaap Liabilities
Liabilities
34663009
CY2020Q4 us-gaap Liabilities
Liabilities
372246
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
316250000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24209
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34190624
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2286
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-34189750
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22714
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
316723259
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394960
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22747817
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2286
us-gaap Operating Income Loss
OperatingIncomeLoss
-22747817
us-gaap Operating Income Loss
OperatingIncomeLoss
-2286
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
24
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
17136
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2074467
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2057307
us-gaap Net Income Loss
NetIncomeLoss
-24805124
us-gaap Net Income Loss
NetIncomeLoss
-2286
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
us-gaap Net Income Loss
NetIncomeLoss
-2286
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22714
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
17451465
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8044125
us-gaap Net Income Loss
NetIncomeLoss
-24805124
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-34189750
us-gaap Net Income Loss
NetIncomeLoss
-24805124
us-gaap Net Income Loss
NetIncomeLoss
-2286
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
17136
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2074467
piii Transaction Costs Associated With Initial Public Offering
TransactionCostsAssociatedWithInitialPublicOffering
234419
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
355188
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21282014
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2286
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1586548
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
316250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-316250000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
309924999
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8325000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
275000
piii Advance From Related Party
AdvanceFromRelatedParty
150000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
275000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
367028
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
120488
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
317757971
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
179512
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-78577
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
179512
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179512
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100935
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179512
piii Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
15450
piii Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
94960
piii Initial Classification Of Classa Common Stock Subject To Possible Redemption
InitialClassificationOfClassaCommonStockSubjectToPossibleRedemption
316250000
CY2021Q1 piii Stock Issuance Costs
StockIssuanceCosts
6827967
CY2021Q1 us-gaap Expense Related To Distribution Or Servicing And Underwriting Fees
ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
6325000
CY2021Q1 piii Other Offering Costs
OtherOfferingCosts
502967
CY2021Q1 piii Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100935
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
316267136
CY2021Q4 piii Net Working Capital
NetWorkingCapital
20793627
CY2021Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current And Noncurrent
AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
200000
CY2021Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
Each Unit consists of one share of Class A common stock and one-third of one redeemable warrant (“Public Warrant”).
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the private warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2021Q4 piii Percentage Of Underwriting Fee On Ipo Proceeds
PercentageOfUnderwritingFeeOnIpoProceeds
0.035
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
8500000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38800
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
480
CY2021Q4 piii Deferred Tax Assets Startup Expenses
DeferredTaxAssetsStartupExpenses
4728629
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4767429
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
480
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4767429
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
480
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4773438
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-480
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4773438
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
480
CY2021Q4 piii Net Operating Loss Carryovers Maximum Offset Percentage
NetOperatingLossCarryoversMaximumOffsetPercentage
0.80
CY2021Q4 piii Net Operating Loss Carryovers Maximum Offset Percentage
NetOperatingLossCarryoversMaximumOffsetPercentage
0.80
CY2021Q3 piii Net Operating Loss Carryovers Maximum Offset Percentage
NetOperatingLossCarryoversMaximumOffsetPercentage
0.80
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4773438
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
480
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0000
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0000
piii Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities
-0.0176
piii Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities
0.0000
piii Effective Income Tax Rate Reconciliation Change In Transaction Costs Incurred In Connection With Ipo
EffectiveIncomeTaxRateReconciliationChangeInTransactionCostsIncurredInConnectionWithIpo
0.0000
piii Effective Income Tax Rate Reconciliation Change In Transaction Costs Incurred In Connection With Ipo
EffectiveIncomeTaxRateReconciliationChangeInTransactionCostsIncurredInConnectionWithIpo
0.0000
piii Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability In Excess Of Proceeds From Private Placement
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityInExcessOfProceedsFromPrivatePlacement
0.0000
piii Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability In Excess Of Proceeds From Private Placement
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityInExcessOfProceedsFromPrivatePlacement
0.0000
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1924
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
12860834

Files In Submission

Name View Source Status
0001104659-23-116284-index-headers.html Edgar Link pending
0001104659-23-116284-index.html Edgar Link pending
0001104659-23-116284.txt Edgar Link pending
0001104659-23-116284-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
piii-20231109.xsd Edgar Link pending
piii-20231109x8k.htm Edgar Link pending
piii-20231109x8k001.jpg Edgar Link pending
piii-20231109xex23d1.htm Edgar Link pending
piii-20231109xex99d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
piii-20231109_cal.xml Edgar Link unprocessable
piii-20231109_def.xml Edgar Link unprocessable
piii-20231109_lab.xml Edgar Link unprocessable
piii-20231109_pre.xml Edgar Link unprocessable
piii-20231109x8k_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending